EV344/#770  Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: a prospective single center, single-arm phase II clinical trial

Shuang Ye; Yi Fu; Shuai Liu; Jun Wang; Lin Zhou; Wei Jiang; Xuan Pei; Wenbin Shen; Min Sun; Boer Shan; Huijuan Yang

doi:10.1136/ijgc-2024-IGCS.463

Article info

E-Poster Viewing Abstracts

AS10. Ovarian cancer

EV344/#770 Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: a prospective single center, single-arm phase II clinical trial

Authors

Shuang Ye Fudan University Shanghai Cancer Center, Shanghai, China PubMed articles Google scholar articles
Yi Fu Fudan University Shanghai Cancer Center, Shanghai, China PubMed articles Google scholar articles
Shuai Liu Fudan University Shanghai Cancer Center, Shanghai, China PubMed articles Google scholar articles
Jun Wang Fudan University Shanghai Cancer Center, Shanghai, China PubMed articles Google scholar articles
Lin Zhou Fudan University Shanghai Cancer Center, Shanghai, China PubMed articles Google scholar articles
Wei Jiang Fudan University Shanghai Cancer Center, Shanghai, China PubMed articles Google scholar articles
Xuan Pei Fudan University Shanghai Cancer Center, Shanghai, China PubMed articles Google scholar articles
Wenbin Shen Fudan University Shanghai Cancer Center, Shanghai, China PubMed articles Google scholar articles
Min Sun Fudan University Shanghai Cancer Center, Shanghai, China PubMed articles Google scholar articles
Boer Shan Fudan University Shanghai Cancer Center, Shanghai, China PubMed articles Google scholar articles
Huijuan Yang Fudan University Shanghai Cancer Center, Shanghai, China PubMed articles Google scholar articles

Citation

Ye S, Fu Y, Liu S, et al

EV344/#770 Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: a prospective single center, single-arm phase II clinical trial

International Journal of Gynecologic Cancer 2024;34:A262-A263.

Publication history

First published October 18, 2024.

Online issue publication

October 18, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password